SMS Pharmaceuticals Limited — Updates, 12-11-2024: Press Release

Revenue from operations for SMS Pharmaceuticals Limited reached ₹196.75 crore in Q2FY25, marking an 18% year-on-year increase, driven by strong demand in the anti-inflammatory and Anti Retro Viral segments. Sequentially, the revenue rose by 20%, contributing to a total of ₹361.20 crore for H1FY25, which is a 20% YoY growth. EBITDA grew by 13% YoY to ₹31.47 crore, with an EBITDA margin stabilizing at 16%. Profit after tax (PAT) saw a significant increase of 20% YoY to ₹14.10 crore, aided by reduced finance costs.

Despite geopolitical tensions affecting gross margins, which were steady at 30%, operational efficiencies cushioned the impact. The company is progressing with its ₹150 crore capex plan for a backward integration project, expecting commercialization in Q4 FY25. Looking forward, SMS Pharma remains optimistic, targeting 20% revenue growth and an EBITDA margin of 20% for FY25, positioning itself favorably within the market as it evolves its product offerings.